The HighWire@HighWireTalk
🚨EXCLUSIVE: If you have a dog and your vet has recommended the Nobivac NXT canine flu vaccine, read this before your next appointment.
Over 1,000 pages of adverse event reports were obtained from the USDA through a FOIA request. They cover Nobivac NXT H3N2, the first self-amplifying RNA vaccine widely used on pets in the United States.
The data covers September 2024 through July 2025 and documents 296 cases listing the vaccine as a suspect product, including deaths, neurological events, anaphylaxis, collapse, and injection-site masses. A 4-year-old golden retriever went into cardiac arrest and died ten minutes after receiving the shot. A 7-year-old Yorkshire Terrier collapsed seventy minutes after vaccination and could not be saved.
Self-amplifying RNA works differently from traditional vaccines. The RNA replicates itself inside the body to produce a sustained immune response, and researchers as recently as April 2025 have written that the mechanisms involved are not fully understood and warrant further investigation.
The USDA approved this vaccine in June 2024. Portions of the pre-approval safety trial data have been withheld as confidential commercial information provided by Merck. Read this entire column and share it with your friends.
Full article by @smiddendorp22 linked below 👇
bit.ly/Dog_Vaccine_AE
